- Home
- INDP
as 11-10-2025 2:17pm EST
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | $140.00 | AVG Volume (30 days): | 67.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -37.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.22 - $47.60 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Indaptus Therapeutics Inc. News
INDP Breaking Stock News: Dive into INDP Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
5 months ago
Indaptus Therapeutics Announces Reverse Stock Split
GlobeNewswire
5 months ago
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
GlobeNewswire
5 months ago
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire
6 months ago
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire
8 months ago
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
GlobeNewswire
8 months ago
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Compare INDP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INDP Indaptus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.